Maralixibat (chloride)

Maralixibat (SHP625) chloride is an orally active ileal bile acid transporter (IBAT) inhibitor. Maralixibat chloride can be used for the research of rare cholestatic liver diseases including Alagille syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC) and biliary atresia[1][2].

Product Specifications

CAS Number

[228113-66-4]

Product Name Alternative

SHP625 (chloride) ; LUM001 (chloride) ; Lopixibat (chloride)

UNSPSC

12352005

Target

Apical Sodium-Dependent Bile Acid Transporter

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/maralixibat-chloride.html

Purity

99.61

Solubility

DMSO : 50 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=S1(CC(CCCC)(CCCC)[C@H](O)[C@H](C2=CC=C(OCC3=CC=C(C[N+]4(CC5)CCN5CC4)C=C3)C=C2)C6=CC(N(C)C)=CC=C61)=O.[Cl-]

Molecular Formula

C40H56ClN3O4S

Molecular Weight

710.41

References & Citations

[1]Shirley M. Maralixibat: First Approval [published correction appears in Drugs. 2021 Dec 6; :]. Drugs. 2022;82 (1) :71-76.|[2]Mayo MJ, et al. A Randomized, Controlled, Phase 2 Study of Maralixibat in the Treatment of Itching Associated With Primary Biliary Cholangitis. Hepatol Commun. 2019 Feb 1;3 (3) :365-381.